Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Revisión del síndrome post-COVID-19 asociado a efluvio telógeno agudo / Review of the post-COVID-19 syndrome associated to acute telogen effluvium
Resumen
Resumen
Introducción: la enfermedad por coronavirus 2019 (COVID-19) ha impactado a nuestra sociedad en numerosos aspectos. Hasta el mes de noviembre de 2022 se han confirmado alrededor de 640 millones de infecciones por SARS-CoV-2 en el mundo.
Objetivo: conocer y comparar la literatura descrita acerca de la asociación de COVID-19 con el desarrollo de efluvio telógeno (ET).
Material y métodos: se realizó una revisión de la literatura acotada a los reportes de casos y bibliografía descrita del ET agudo asociado al síndrome post-COVID-19. Se muestran diversas aportaciones sobre esta entidad hasta el momento.
Resultados: posterior al análisis de los estudios seleccionados, llevados a cabo en España, Italia, Irak y los EUA, se identificó mayor presencia de efluvio telógeno en pacientes con COVID-19 diagnosticado mediante prueba confirmatoria por PCR, siendo: del sexo femenino, con edades de más de 40 años, con atención ambulatoria y tratamiento tópico.
Conclusiones: el análisis evidencia que los pacientes con COVID-19 están expuestos a múltiples factores predisponentes para el desarrollo del ET; alrededor de 1 de cada 10 pacientes que padecen de ET agudo tuvieron alguna infección subclínica por el virus.
Abstract
Background: The coronavirus disease 2019 (COVID-19) has impacted our society in numerous aspects. As of November 2022, around 640 million SARS-CoV-2 infections have been confirmed worldwide.
Objective: To know and compare the literature described about the association of COVID-19 with the development of telogen effluvium (TE).
Material and methods: A review of the literature limited to case reports and described bibliography of acute TE associated with post-COVID-19 syndrome was carried out. Various contributions on this entity are shown so far.
Results: After the analysis of the selected studies, carried out in Spain, Italy, Iraq and the USA, a greater presence of telogen effluvium was identified in patients with COVID-19 diagnosed by confirmatory PCR test, being mainly female, aged over 40 years, with outpatient care and topical treatment.
Conclusions: The analysis shows that patients with COVID-19 are exposed to multiple predisposing factors for the development of TE; about 1 in 10 patients suffering from acute TE had some subclinical infection by the virus.
Palabras clave
Texto completo:
PDFReferencias
Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium. Ir J Med Sci. 2022;191(4):1677-81. doi: 10.1007/s11845-021-02754-5.
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nature Medicine. 2021;27(4):601-615. doi: 10.1038/ s41591-021-01283-z.
Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nature Medicine. 2020;26(7):1017- 1032. Nature Research. doi: 10.1038/s41591-020-0968-3.
Shah W, Hillman T, Playford ED et al. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;136. doi: 10.1136/bmj.n136.
Miyazato Y, Morioka S, Tsuzuki S, et al. Prolonged and Late Onset Symptoms of Coronavirus Disease 2019. Open Forum Infectious Diseases. 2020;7(11). doi: 10.1093/ofid/ofaa507.
Arenas Soto, C. M., & Diaz Mestre, M. P. (2022). Efluvio telógeno: una manifestación del síndrome post-COVID-19. Piel, 37, S7-S9. https://doi.org/10.1016/j.piel.2021.06.013.
Moncada-Bustamante I. Reporte de Caso: efluvio telógeno agudo post COVID-19 asociado a receptores androgénicos. Revista Médica Hondureña. 2022;90(1):57-61. doi: 10.5377/ rmh.v90i1.14181.
Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.
Marraha F, al Faker I, Gallouj S. A Review of the Dermatological Manifestations of Coronavirus Disease 2019 (COVID-19). Dermatology Research and Practice. 2020:1-9. doi: 10.1155/2020/9360476.
Fahmy DH, El-Amawy HS, El-Samongy MA, et al. COVID-19 and dermatology: a comprehensive guide for dermatologists. Journal of the European Academy of Dermatology and Venereology. 2020;34(7):1388-1394. doi: 10.1111/jdv.16545.
Moreno-Arrones OM, Lobato-Berezo A, Gomez-Zubiaur A, et al. SARS-CoV-2-induced telogen effluvium: a multicentric study. Journal of the European Academy of Dermatology and Venereology. JEADV. 2021;35(3):e181-e183. doi: 10.1111/ jdv.17045.
Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatologic Therapy. 2021; 34(1). doi: 10.1111/dth.14547.
Mysore V, Parthasaradhi A, Kharkar R, et al. Expert consensus on the management of telogen effluvium in India. International Journal of Trichology. 2019;11(3):107. doi: 10.4103/ijt.ijt_23_19.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. Journal of Infection. 2020;80 (6):607-613. doi: 10.1016/j.jinf.2020.03.037.
Di Landro A, Naldi L, Glaser E, et al. Pathobiology questions raised by telogen effluvium and trichodynia in COVID-19 patients. Experimental Dermatology. 2021;30(7):999-1000. doi: 10.1111/exd.14352.
Abrantes TF, Artounian KA, Falsey R, et al. Time of onset and duration of post-COVID-19 acute telogen effluvium. Journal of the American Academy of Dermatology. 2021;85(4):975-976. doi: 10.1016/j.jaad.2021.07.021.
Ricardo-Criado P, Pincelli TPH, Criado RFJ, et al. Potential interactions of SARS-CoV-2 with human cell receptors in the skin: Understanding the enigma for a lower frequency of skin lesions compared to other tissues. Experimental Dermatology. 2020;29(10):936-944. doi: 10.1111/exd.14186.
Olds H, Liu J, Luk K, et al. Telogen effluvium associated with COVID-19 infection. Dermatologic Therapy. 2021;34(2). doi: 10.1111/dth.14761.
Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID-19 emergency: Psychological implications. Dermatologic Therapy. 2020;33(4). doi: 10.1111/dth.13648.
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine. 2020;8(6):e46-e47. doi: 10.1016/S2213 -2600(20)30216-2.
Starace M, Iorizzo M, Sechi A, et al. Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD International. 2021;5:11-18. doi: 10.1016/j.jdin.2021.07.006.
Mieczkowska K, Deutsch A, Borok J, et al. Telogen effluvium: a sequela of COVID-19. International Journal of Dermatology. 2021;60(1):122-124. doi: 10.1111/ijd.15313.
Saki N, Aslani FS, Sepaskhah M, et al. Intermittent chronic telogen effluvium with an unusual dermoscopic finding following COVID-19. Clin Case Rep. 2022;10(8):e6228. doi: 10.1002/ccr3.6228.
Aksoy H, Yıldırım UM, Ergen P, et al. COVID-19 induced telogen effluvium. Dermatologic Therapy. 2021;34(6). doi: 10.1111/dth.15175.
Kutlu Ö, Metin A. Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic. Dermatologic Therapy. 2020;33(6). doi: 10.1111/dth.14096.
Cline A, Kazemi A, Moy J, et al. A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by COVID-19. Journal of the American Academy of Dermatology. 2021;84(3):773-775. doi: 10.1016/j. jaad.2020.11.032.
Inamadar A. Covid induced telogen effluvium (CITE): An insight. Indian Dermatology Online Journal. 2022;13(4):445. doi: 10.4103/idoj.idoj_139_22.
Enlaces refback
- No hay ningún enlace refback.